AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AMRN · NASDAQ · Drug Manufacturers - General

Amarin (ADR) (AMRN)

Commercializes icosapent ethyl for cardiovascular care through Vascepa and Vazkepa.

$13.75

After hours−0.08 (−0.58%)

At close$13.83(+2.60%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	66	75	57	68	42	62	42	73	50	49	45	42
Cost of revenue	36	30	25	26	26	72	17	22	27	27	27	27
Gross profit	30	45	32	42	16	−10	25	50	22	22	18	15
	51	50	45	43	41	43	42	66	33	25	26	27
Research & development	5	6	6	4	5	6	5	5	4	5	5	5
	45	44	40	39	37	37	37	39	20	20	21	22
Selling & marketing	24	23	20	20	19	20	17	15	5	4	4	3
General & administrative	21	21	19	18	18	17	20	24	14	16	17	19
Other expenses	1	0	0	0	0	0	0	23	9	0	0	0
Operating income	−21	−5	−14	−1	−25	−53	−17	−16	−11	−2	−8	−12
	3	2	5	3	4	3	3	3	3	1	−1	4
Interest income	3	3	3	3	3	3	3	3	3	3	2	3
Interest expense	0	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	−1	−3	−5	−3	−4	−15	−3	−23	−9	−1	0	0
Income before tax	−19	−2	−9	3	−22	−50	−14	−13	−8	−1	−9	−8
Income tax expense	1	3	1	1	4	−1	2	1	0	0	2	0
Net income from continuing operations	−19	−6	−10	2	−25	−49	−16	−14	−8	−1	−11	−8
Net income	−19	−6	−10	2	−25	−49	−16	−14	−8	−1	−11	−8
EPS, basic	−$0.95	−$0.29	−$0.49	$0.07	−$1.22	−$2.37	−$0.76	−$0.68	−$0.37	−$0.06	−$0.60	−$0.40
EPS, diluted	−$0.95	−$0.29	−$0.49	$0.07	−$1.22	−$2.37	−$0.76	−$0.68	−$0.37	−$0.06	−$0.60	−$0.40
Weighted average shares, basic	20	20	21	21	21	21	21	21	21	21	21	21
Weighted average shares, diluted	20	20	21	21	21	21	21	21	21	21	21	21
EBITDA	−20	−1	−8	4	−21	−37	−13	8	−1	0	−7	−11
Depreciation & amortization	1	1	1	1	1	1	1	1	1	1	1	1
EBIT	−21	−2	−9	3	−22	−38	−14	7	−2	−1	−8	−12